Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Trius Therapeutics Inc (TRSX) since 2010 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Trius Therapeutics Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 1356857.
Total stock buying since 2010: $50,281,491.
Total stock sales since 2010: $1,444,811.
Total stock option exercises since 2010: $355,266.
▪ Recent SEC 13D filings for all companies
▪ Recent portfolio reports of all companies
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2013 | 0 | $0 | 121,000 | $1,016,197 | 40,000 | $160,000 |
| 2012 | 0 | $0 | 35,022 | $193,782 | 110,310 | $131,518 |
| 2011 | 2,133 | $14,461 | 32,661 | $234,832 | 8,070 | $4,196 |
| 2010 | 10,053,706 | $50,267,030 | 0 | $0 | 59,715 | $59,552 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2013-07 | 0 | $0 | 35,000 | $340,325 | 20,000 | $80,000 |
| 2013-06 | 0 | $0 | 8,000 | $67,489 | 0 | $0 |
| 2013-05 | 0 | $0 | 76,000 | $594,183 | 20,000 | $80,000 |
| 2013-04 | 0 | $0 | 500 | $3,550 | 0 | $0 |
| 2013-03 | 0 | $0 | 1,500 | $10,650 | 0 | $0 |
| 2012-06 | 0 | $0 | 1,800 | $10,800 | 0 | $0 |
| 2012-03 | 0 | $0 | 500 | $2,520 | 106,310 | $129,438 |
| 2012-02 | 0 | $0 | 500 | $2,815 | 0 | $0 |
| 2012-01 | 0 | $0 | 32,222 | $177,647 | 4,000 | $2,080 |
| 2011-12 | 0 | $0 | 700 | $5,250 | 0 | $0 |
| 2011-11 | 0 | $0 | 2,387 | $17,992 | 0 | $0 |
| 2011-10 | 0 | $0 | 4,674 | $33,429 | 4,000 | $2,080 |
| 2011-09 | 0 | $0 | 1,600 | $10,430 | 0 | $0 |
| 2011-08 | 2,133 | $14,461 | 1,500 | $9,410 | 4,070 | $2,116 |
| 2011-07 | 0 | $0 | 2,800 | $21,195 | 0 | $0 |
| 2011-06 | 0 | $0 | 2,800 | $22,543 | 0 | $0 |
| 2011-05 | 0 | $0 | 11,600 | $86,089 | 0 | $0 |
| 2011-04 | 0 | $0 | 1,000 | $5,508 | 0 | $0 |
| 2011-03 | 0 | $0 | 2,600 | $17,486 | 0 | $0 |
| 2011-02 | 0 | $0 | 1,000 | $5,500 | 0 | $0 |
| 2010-12 | 0 | $0 | 0 | $0 | 22,700 | $11,804 |
| 2010-11 | 1,000 | $3,500 | 0 | $0 | 7,364 | $9,499 |
| 2010-10 | 0 | $0 | 0 | $0 | 29,651 | $38,249 |
| 2010-08 | 10,052,706 | $50,263,530 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2013-07-22 | Finn John (Chief Scientific Officer) | Sale | 1,000 | 12.10 | 12,100 |
| 2013-07-15 | Finn John (Chief Scientific Officer) | Sale | 3,500 | 10.55 | 36,925 |
| 2013-07-12 | Finn John (Chief Scientific Officer) | Sale | 5,000 | 10.10 | 50,500 |
| 2013-07-11 | Morneau Michael (VP Finance & CAO) | Sale | 20,000 | 9.75 | 195,000 |
| 2013-07-11 | Morneau Michael (VP Finance & CAO) | Option Ex | 20,000 | 4.00 | 80,000 |
| 2013-07-11 | Finn John (Chief Scientific Officer) | Sale | 500 | 9.32 | 4,660 |
| 2013-07-10 | Finn John (Chief Scientific Officer) | Sale | 1,000 | 8.58 | 8,580 |
| 2013-07-01 | Prokocimer Philippe (Chief Medical Officer) | Sale | 2,000 | 8.14 | 16,280 |
| 2013-07-01 | Bartizal Ken (Chief Development Officer) | Sale | 2,000 | 8.14 | 16,280 |
| 2013-06-12 | Finn John (Chief Scientific Officer) | Sale | 3,000 | 9.08 | 27,249 |
| 2013-06-11 | Finn John (Chief Scientific Officer) | Sale | 1,000 | 8.94 | 8,940 |
| 2013-06-04 | Bartizal Ken (Chief Development Officer) | Sale | 2,000 | 7.90 | 15,800 |
| 2013-06-03 | Prokocimer Philippe (Chief Medical Officer) | Sale | 2,000 | 7.75 | 15,500 |
| 2013-05-24 | Prokocimer Philippe (Chief Medical Officer) | Sale | 12,000 | 7.93 | 95,124 |
| 2013-05-24 | Bartizal Ken (Chief Development Officer) | Sale | 12,000 | 7.93 | 95,124 |
| 2013-05-14 | Morneau Michael (VP Finance & CAO) | Sale | 20,000 | 7.75 | 155,000 |
| 2013-05-14 | Morneau Michael (VP Finance & CAO) | Option Ex | 20,000 | 4.00 | 80,000 |
| 2013-05-14 | Finn John (Chief Scientific Officer) | Sale | 5,000 | 8.10 | 40,510 |
| 2013-05-14 | Bartizal Ken (Chief Development Officer) | Sale | 12,000 | 7.85 | 94,200 |
| 2013-05-13 | Prokocimer Philippe (Chief Medical Officer) | Sale | 12,000 | 7.65 | 91,800 |
| 2013-05-10 | Finn John (Chief Scientific Officer) | Sale | 3,000 | 7.47 | 22,425 |
| 2013-04-24 | Finn John (Chief Scientific Officer) | Sale | 500 | 7.10 | 3,550 |
| 2013-03-15 | Finn John (Chief Scientific Officer) | Sale | 1,500 | 7.10 | 10,650 |
| 2012-06-22 | Schmid John P. (CFO and Secretary) | Sale | 1,800 | 6.00 | 10,800 |
| 2012-03-27 | Schmid John P. (CFO and Secretary) | Option Ex | 5,000 | 1.29 | 6,450 |
| 2012-03-27 | Stein Jeffrey (President and CEO) | Option Ex | 38,462 | .52 | 20,000 |
| 2012-03-27 | Eastham Karin (Director) | Option Ex | 6,000 | 3.50 | 21,000 |
| 2012-03-26 | O'leary Brendan (Director) | Option Ex | 21,302 | 2.65 | 56,343 |
| 2012-03-26 | Finn John (Chief Scientific Officer) | Option Ex | 20,000 | .52 | 10,400 |
| 2012-03-26 | Powell Michael (Director) | Option Ex | 9,302 | 1.29 | 11,999 |
| 2012-03-23 | Prokocimer Philippe (Chief Medical Officer) | Option Ex | 6,244 | .52 | 3,246 |
| 2012-03-01 | Schmid John P. (CFO and Secretary) | Sale | 500 | 5.04 | 2,520 |
| 2012-02-02 | Schmid John P. (CFO and Secretary) | Sale | 500 | 5.63 | 2,815 |
| 2012-01-19 | Powell Michael (Director) | Sale | 2,600 | 5.64 | 14,661 |
| 2012-01-18 | Powell Michael (Director) | Sale | 4,300 | 5.56 | 23,895 |
| 2012-01-17 | Powell Michael (Director) | Sale | 16,100 | 5.43 | 87,423 |
| 2012-01-13 | Prokocimer Philippe (Chief Medical Officer) | Option Ex | 4,000 | .52 | 2,080 |
| 2012-01-13 | Powell Michael (Director) | Sale | 8,522 | 5.46 | 46,572 |
| 2012-01-03 | Schmid John P. (CFO and Secretary) | Sale | 700 | 7.28 | 5,096 |
| 2011-12-01 | Schmid John P. (CFO and Secretary) | Sale | 700 | 7.50 | 5,250 |
| 2011-11-17 | Bartizal Ken (Chief Development Officer) | Sale | 1,687 | 7.85 | 13,242 |
| 2011-11-07 | Schmid John P. (CFO and Secretary) | Sale | 100 | 7.00 | 700 |
| 2011-11-01 | Schmid John P. (CFO and Secretary) | Sale | 600 | 6.75 | 4,050 |
| 2011-10-31 | Prokocimer Philippe (Chief Medical Officer) | Sale | 1,687 | 7.45 | 12,568 |
| 2011-10-27 | Prokocimer Philippe (Chief Medical Officer) | Sale | 1,687 | 7.45 | 12,568 |
| 2011-10-26 | Schmid John P. (CFO and Secretary) | Sale | 200 | 7.00 | 1,400 |
| 2011-10-11 | Finn John (Chief Scientific Officer) | Sale | 500 | 6.19 | 3,095 |
| 2011-10-04 | Prokocimer Philippe (Chief Medical Officer) | Option Ex | 4,000 | .52 | 2,080 |
| 2011-10-03 | Schmid John P. (CFO and Secretary) | Sale | 600 | 6.33 | 3,798 |
| 2011-09-15 | Finn John (Chief Scientific Officer) | Sale | 1,000 | 6.47 | 6,470 |
| 2011-09-01 | Schmid John P. (CFO and Secretary) | Sale | 600 | 6.60 | 3,960 |
| 2011-08-29 | Truex Paul F (Director) | Buy | 2,000 | 6.80 | 13,600 |
| 2011-08-22 | Thompson John Craig (Chief Commercial Officer) | Buy | 133 | 6.48 | 861 |
| 2011-08-22 | Prokocimer Philippe (Chief Medical Officer) | Option Ex | 4,070 | .52 | 2,116 |
| 2011-08-12 | Finn John (Chief Scientific Officer) | Sale | 300 | 7.00 | 2,100 |
| 2011-08-11 | Finn John (Chief Scientific Officer) | Sale | 200 | 7.00 | 1,400 |
| 2011-08-09 | Finn John (Chief Scientific Officer) | Sale | 1,000 | 5.91 | 5,910 |
| 2011-07-20 | Finn John (Chief Scientific Officer) | Sale | 500 | 8.00 | 4,000 |
| 2011-07-20 | Schmid John P. (CFO and Secretary) | Sale | 100 | 8.00 | 800 |
| 2011-07-12 | Finn John (Chief Scientific Officer) | Sale | 1,500 | 7.23 | 10,845 |
| 2011-07-01 | Schmid John P. (CFO and Secretary) | Sale | 700 | 7.93 | 5,550 |
| 2011-06-09 | Finn John (Chief Scientific Officer) | Sale | 2,000 | 8.09 | 16,187 |
| 2011-06-01 | Schmid John P. (CFO and Secretary) | Sale | 800 | 7.95 | 6,356 |
| 2011-05-16 | Finn John (Chief Scientific Officer) | Sale | 7,000 | 8.02 | 56,161 |
| 2011-05-16 | Schmid John P. (CFO and Secretary) | Sale | 400 | 8.00 | 3,200 |
| 2011-05-12 | Finn John (Chief Scientific Officer) | Sale | 1,500 | 7.00 | 10,500 |
| 2011-05-10 | Finn John (Chief Scientific Officer) | Sale | 1,000 | 6.02 | 6,018 |
| 2011-05-05 | Schmid John P. (CFO and Secretary) | Sale | 200 | 7.00 | 1,400 |
| 2011-05-03 | Finn John (Chief Scientific Officer) | Sale | 800 | 6.00 | 4,800 |
| 2011-05-03 | Schmid John P. (CFO and Secretary) | Sale | 200 | 6.00 | 1,200 |
| 2011-05-02 | Schmid John P. (CFO and Secretary) | Sale | 500 | 5.62 | 2,810 |
| 2011-04-11 | Finn John (Chief Scientific Officer) | Sale | 500 | 5.36 | 2,678 |
| 2011-04-01 | Schmid John P. (CFO and Secretary) | Sale | 500 | 5.66 | 2,830 |
| 2011-03-30 | Finn John (Chief Scientific Officer) | Sale | 200 | 6.00 | 1,200 |
| 2011-03-09 | Finn John (Chief Scientific Officer) | Sale | 500 | 5.86 | 2,930 |
| 2011-03-01 | Finn John (Chief Scientific Officer) | Sale | 500 | 7.00 | 3,500 |
| 2011-03-01 | Schmid John P. (CFO and Secretary) | Sale | 1,400 | 7.04 | 9,856 |
| 2011-02-18 | Finn John (Chief Scientific Officer) | Sale | 500 | 6.00 | 3,000 |
| 2011-02-17 | Finn John (Chief Scientific Officer) | Sale | 500 | 5.00 | 2,500 |
| 2010-12-15 | Stein Jeffrey (President and CEO) | Option Ex | 22,700 | .52 | 11,804 |
| 2010-11-23 | Truex Paul F (Director) | Buy | 1,000 | 3.50 | 3,500 |
| 2010-11-23 | Truex Paul F (Director) | Option Ex | 7,364 | 1.29 | 9,499 |
| 2010-10-08 | Kabakoff David S (Director) | Option Ex | 29,651 | 1.29 | 38,249 |
| 2010-08-06 | Kpcb Pbd Associates, Llc (10% Owner) | Buy | 828,807 | 5.00 | 4,144,035 |
| 2010-08-06 | Kpcb Pbd Founders Fund, Llc (10% Owner) | Buy | 4,901 | 5.00 | 24,505 |
| 2010-08-06 | Versant Side Fund Iii, L.p. (10% Owner) | Buy | 914,529 | 5.00 | 4,572,645 |
| 2010-08-06 | Kjellson Nina S (Director) | Buy | 1,227,333 | 5.00 | 6,136,665 |
| 2010-08-06 | Pepper Douglas A (Other) | Buy | 1,227,333 | 5.00 | 6,136,665 |
| 2010-08-06 | Sofinnova Venture Partners Vii L P (10% Owner) | Buy | 830,000 | 5.00 | 4,150,000 |
| 2010-08-06 | Kpcb Pandemic & Bio Defense Fund Llc (10% Owner) | Buy | 823,906 | 5.00 | 4,119,530 |
| 2010-08-06 | Cleveland Bruce A (Other) | Buy | 1,227,333 | 5.00 | 6,136,665 |
| 2010-08-06 | Prism Venture Partners V-a Lp (10% Owner) | Buy | 1,194,035 | 5.00 | 5,970,175 |
| 2010-08-06 | Atwood Brian G (Director) | Buy | 914,529 | 5.00 | 4,572,645 |
| 2010-08-06 | Powell Michael (Director) | Buy | 830,000 | 5.00 | 4,150,000 |
| 2010-08-06 | Kabakoff David S (Director) | Buy | 30,000 | 5.00 | 150,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of TRSX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Trius Therapeutics Inc (symbol TRSX, CIK number 1356857) see the Securities and Exchange Commission (SEC) website.